{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:45:31Z","timestamp":1782449131733,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T00:00:00Z","timestamp":1434758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12889-015-1928-6","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T07:05:12Z","timestamp":1434697512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana"],"prefix":"10.1186","volume":"15","author":[{"given":"Raymond A.","family":"Tetteh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund T.","family":"Nartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla A.","family":"Nortey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N. O.","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,20]]},"reference":[{"issue":"11","key":"1928_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMcp020892","volume":"348","author":"JL Gerberding","year":"2003","unstructured":"Gerberding JL. Occupational exposure to HIV in health care settings. N Engl J Med. 2003;348(11):826\u201333.","journal-title":"N Engl J Med"},{"key":"1928_CR2","series-title":"HIV and STI Division","volume-title":"Summary of Published Reports: 1999","author":"Collaborators CDSCa","year":"1999","unstructured":"Collaborators CDSCa. Occupational Transmission of HIV. In: Summary of Published Reports: 1999, HIV and STI Division. 1999."},{"issue":"RR-1","key":"1928_CR3","first-page":"1","volume":"39","author":"CDC","year":"1990","unstructured":"CDC. Public Health Service Statement on Management of Occupational Exposure to Human Immunodeficiency Virus, including considerations regarding Zidovudine Post Exposure use. MMWR. 1990;39(RR-1):1\u201314.","journal-title":"MMWR"},{"issue":"21","key":"1928_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199711203372101","volume":"337","author":"DM Cardo","year":"1997","unstructured":"Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case\u2013control study of HIV seroconversion in health care workers after percutaneous exposure: Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337(21):1485\u201390.","journal-title":"N Engl J Med"},{"issue":"5B","key":"1928_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0002-9343(97)00068-5","volume":"102","author":"DJ Manion","year":"1997","unstructured":"Manion DJ, Hirsch MS. Combination chemotherapy for human immunodeficiency virus-1. Am J Med. 1997;102(5B):76\u201380. discussion 81\u201372.","journal-title":"Am J Med"},{"issue":"5","key":"1928_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1086\/516442","volume":"175","author":"A Lafeuillade","year":"1997","unstructured":"Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175(5):1051\u20135.","journal-title":"J Infect Dis"},{"key":"1928_CR7","volume-title":"HIV post-exposure prophylaxis: Guidance from the UK chief Medical Officer Expert Advisory Group on AIDS","author":"Health UDo","year":"2008","unstructured":"Health UDo. HIV post-exposure prophylaxis: Guidance from the UK chief Medical Officer Expert Advisory Group on AIDS. 2008."},{"key":"1928_CR8","unstructured":"NACP, ed: 2011 HIV Sentinel Survey Report: National Aids Control Program of Ghana; 2012."},{"key":"1928_CR9","doi-asserted-by":"crossref","unstructured":"Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C: Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol 2012;12:7.","DOI":"10.1186\/1472-6904-12-7"},{"issue":"1","key":"1928_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002030-200201040-00010","volume":"16","author":"GL Dean","year":"2002","unstructured":"Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids. 2002;16(1):75\u201383.","journal-title":"Aids"},{"issue":"2","key":"1928_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1086\/422141","volume":"39","author":"X Duval","year":"2004","unstructured":"Duval X, Journot V, Leport C, Chene G, Dupon M, Cuzin L, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004;39(2):248\u201355.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1928_CR12","first-page":"229","volume":"170","author":"V Montessori","year":"2004","unstructured":"Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. Cmaj. 2004;170(2):229\u201338.","journal-title":"Cmaj"},{"key":"1928_CR13","volume-title":"Pharmacovigilance for antiretrovirals in resource poor countries. Medicines policy and standards","author":"WHO","year":"2007","unstructured":"WHO. Pharmacovigilance for antiretrovirals in resource poor countries. Medicines policy and standards. Geneva: World Health Organization; 2007."},{"issue":"4","key":"1928_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","volume":"34","author":"ME O\u2019Brien","year":"2003","unstructured":"O\u2019Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4):407\u201314.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"1928_CR15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1086\/501736","volume":"21","author":"SA Wang","year":"2000","unstructured":"Wang SA, Panlilio AL, Doi PA, White AD, Stek Jr M, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol. 2000;21(12):780\u20135.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1928_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2165\/00002018-200124080-00003","volume":"24","author":"LM Lee","year":"2001","unstructured":"Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf. 2001;24:587\u201397.","journal-title":"Drug Saf"},{"issue":"5","key":"1928_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/00126334-200204150-00019","volume":"29","author":"P Braitstein","year":"2002","unstructured":"Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O\u2019Shaughnessy MV, et al. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquir Immune Defic Syndr. 2002;29(5):547\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1928_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350000500303","volume":"5","author":"T Quirino","year":"2000","unstructured":"Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, et al. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther. 2000;5(3):195\u20137.","journal-title":"Antivir Ther"},{"issue":"9205","key":"1928_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S0140-6736(99)05005-9","volume":"355","author":"JM Parkin","year":"2000","unstructured":"Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet. 2000;355(9205):722\u20133.","journal-title":"Lancet"},{"key":"1928_CR20","first-page":"CD002835","volume":"1","author":"TN Young","year":"2007","unstructured":"Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford G. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007;1:CD002835.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1928_CR21","first-page":"205","volume":"40","author":"V Puro","year":"2005","unstructured":"Puro V, De Carli G, Ippolito G. Postexposure HIV prophylaxis regimen. Clin Infect Dis. 2005;40(1):205\u20136.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"1928_CR22","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/00002030-200309050-00020","volume":"17","author":"V Puro","year":"2003","unstructured":"Puro V, Soldani F, De Carli G, Lazarevic Z, Mattioli F, Ippolito G. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. Aids. 2003;17(13):1988\u201390.","journal-title":"Aids"},{"issue":"3","key":"1928_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2125.1998.00774.x","volume":"46","author":"RD Mann","year":"1998","unstructured":"Mann RD. Prescription-event monitoring\u2013recent progress and future horizons. Br J Clin Pharmacol. 1998;46(3):195\u2013201.","journal-title":"Br J Clin Pharmacol"},{"key":"1928_CR24","doi-asserted-by":"publisher","unstructured":"Tetteh RA, Nartey ET, Lartey M, Mantel-Teeuwisse AK, Leufkens HG, Nortey PA, Dodoo AN. Outcomes of a Postexposure Prophylaxis Program at the Korle-Bu Teaching Hospital in Ghana: a Retrospective Cohort Study. J Int Assoc Provid AIDS Care. 2013. doi: 10.1177\/2325957413508321","DOI":"10.1177\/2325957413508321"},{"key":"1928_CR25","unstructured":"CDC. Updated U.S Public Health service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR. 2005;54(Number RR--9):1\u201317"},{"key":"1928_CR26","doi-asserted-by":"crossref","unstructured":"Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schuhmacher H, May T, Canton P: Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001;32(10):1494\u20131495.","DOI":"10.1086\/320166"},{"key":"1928_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/135965350801300109","volume":"13","author":"M Loutfy","year":"2008","unstructured":"Loutfy M, Macdonald S, Myhr T, Husson H, Du-Mont J, Balla S. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther. 2008;13:87\u201395.","journal-title":"Antivir Ther"},{"issue":"1","key":"1928_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","volume":"11","author":"R Sacks","year":"2010","unstructured":"Sacks R, Walsh J. Comparing the tolerability of two HIV post-exposure prophylaxis regimens. HIV Med. 2010;11(1):1\u2013119.","journal-title":"HIV Med"},{"issue":"12","key":"1928_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/00043764-199812000-00010","volume":"40","author":"RB Swotinsky","year":"1998","unstructured":"Swotinsky RB, Steger KA, Sulis C, Snyder S, Craven DE. Occupational exposure to HIV: experience at a tertiary care center. J Occup Environ Med. 1998;40(12):1102\u20139.","journal-title":"J Occup Environ Med"},{"issue":"12","key":"1928_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-118-12-199306150-00001","volume":"118","author":"JI Tokars","year":"1993","unstructured":"Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, Bandea CI, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood: the CDC Cooperative Needlestick Surveillance Group. Ann Intern Med. 1993;118(12):913\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1928_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/apc.2006.20.258","volume":"20","author":"MO Johnson","year":"2006","unstructured":"Johnson MO, Chesney MA, Goldstein RB, Remien RH, Catz S, Gore-Felton C, et al. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: a mediation model. AIDS Patient Care STDS. 2006;20(4):258\u201368.","journal-title":"AIDS Patient Care STDS"},{"issue":"RR-7","key":"1928_CR32","first-page":"1","volume":"47","author":"CDC","year":"1998","unstructured":"CDC. Public Health Service guidelines for the Management of Health- Care Worker Exposures to HIV and Recommendations for Post exposure Prophylaxis. MMWR. 1998;47(RR-7):1\u201333.","journal-title":"MMWR"},{"issue":"5","key":"1928_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"D Morisky","year":"2008","unstructured":"Morisky D, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348\u201354.","journal-title":"J Clin Hypertens"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-015-1928-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-015-1928-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-015-1928-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-015-1928-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T05:12:09Z","timestamp":1652505129000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-015-1928-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1186\/s12889-015-1928-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,20]]},"article-number":"573"}}